150 related articles for article (PubMed ID: 19681902)
1. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
[TBL] [Abstract][Full Text] [Related]
2. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
4. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
5. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
[TBL] [Abstract][Full Text] [Related]
6. The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
Gurbuz C; Canat L; Atis G; Guner B; Caskurlu T
Kaohsiung J Med Sci; 2012 Dec; 28(12):649-53. PubMed ID: 23217356
[TBL] [Abstract][Full Text] [Related]
7. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
8. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
Rhoden EL; Riedner CE; Morgentaler A
J Urol; 2008 May; 179(5):1741-4. PubMed ID: 18343420
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
10. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
[TBL] [Abstract][Full Text] [Related]
11. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
Ochiai A; Fritsche HA; Babaian RJ
Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
[TBL] [Abstract][Full Text] [Related]
12. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
13. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Presti JC; Hovey R; Carroll PR; Shinohara K
J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
[TBL] [Abstract][Full Text] [Related]
15. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
18. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
19. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
20. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels.
Cookson MS; Floyd MK; Ball TP; Miller EK; Sarosdy MF
J Urol; 1995 Sep; 154(3):1070-3. PubMed ID: 7543601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
